Fondazione IRCCS Policlinico San Matteo
N° Verde Prenotazioni (rete fissa) 800.638638 | 02 99.95.99 (da cellulare)
       
Gruppi di Ricerca

Ematologia Traslazionale - Gruppo di Ricerca

REFERENTE - GROUP LEADER
Prof. ARCAINI Luca
CURRICULUM VITAE REFERENTE

CV Prof. Arcaini Luca

 
GROUP MEMBERS

Marzia Varettoni, Silvia Mangiacavalli, Patrizia Zappasodi, Marianna Rossi, Manuel Gotti, Elisa Roncoroni, Roberta Sciarra, Claudio Cartia, Irene Defrancesco, Antonio Bianchessi, Silvia Zibellini, Cristina Picone.

 

  •  

    RESEARCH PROJECTS

    In lymphoid neoplasms the aim it to investigate the mechanisms underlying rare B-cell lymphoproliferative disorders (lymphomas associated with HCV infection or with autoimmune diseases, unclussified) through the precision medicine methodology; a machine learning approach will also been applied combing clinical, histological and molecular data to ameliorate diagnostic assessment.
    Investigations of drivers of lymphoma and CLL development may help us better identify clinical and prognostically features of and could provide suggestions to define a better nosological classification and to set up a personalized management of this hard-to-treat setting of patients.
    Other field of investigation is the role of endothelial dysfunction in the setting of allogeneic transplant and CAR-T.
    In acute leukemia our projects range over different topics, from pharmacokinetics to molecular biology, to immunology. Specifically, in collaboration with othercenters, we have a running project on the pharmacokinetics of the BCL2 inhibitor Venetoclax in combination with azoles in treating the AML of the elderly. Moreover, we are conducting a multicenter study on the molecular pathogenesis of rare type of acute leukemia by using a next generation sequencing approach.Eventually, we are exploring the role of the bone marrow microenvironment in the mechanism of resistance to chemiotherapy, by studying the bone marrow mesenchimal cells in NPM1 mutated AML.
  •  

    5 BEST PAPERS

  •  

    AVAILABLE TECHNOLOGY

  •  

    RUNNING FUNDS

  •  

    NATIONAL AND INTERNATIONAL STRATEGIC COLLABORATIONS